Regaining compliance with Nasdaq's equity requirements is a positive development for Traws Pharma, as it ensures the company's continued listing on the NASDAQ Capital Market. This reduces the risk of delisting, which could have negatively impacted investor confidence and stock price. The news is likely to have a positive short-term impact on TRAW's stock price.